{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:45Z","timestamp":1790014725506,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Mycophenolate Mofetil (MMF) has become one of the cornerstone treatments of lupus nephritis (LN). It is converted into mycophenolic acid (MPA), an active metabolite, that displays high inter- and intra-individual pharmacokinetic variability. However, the routine monitoring of MPA trough level is still debatable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The present study aims to evaluate the relationship between MPA trough levels and both clinical outcomes and drug-related adverse effects during the maintenance phase of LN in Egyptian patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We included thirty-five adults and twenty-nine children with biopsy-proven class III and IV LN, who had been maintained on steroid and MMF as maintenance therapy for more than six months. Clinical and laboratory markers of lupus activity as well as MMF adverse events were reported. MPA trough levels were measured by High-Performance Liquid Chromatography (HPLC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There was a significant association between low MPA trough levels and both flares and SLEDAI scores in the adult group (<jats:italic>P<\/jats:italic>\u2009=\u20090.027 and 0.019, respectively). Moreover, high MPA trough levels were associated with higher risk of gastritis in the same age group (<jats:italic>P<\/jats:italic>\u2009=\u20090.007). There was no significant association with any of the parameters studied in the pediatric group. Gastritis was the most frequent side effect in both age groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>MPA trough levels correlated with disease activity and gastritis in adult LN patients, and this may help to optimize MMF dosage in these patients. However, MPA concentration-effect relationships were not observed in pediatric patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12969-025-01074-7","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:44:56Z","timestamp":1741783496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mycophenolic acid trough level assessment in patients with lupus nephritis; does it make a difference?"],"prefix":"10.1186","volume":"23","author":[{"given":"Ahmed E.","family":"Abdulgalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha H.","family":"Elnagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal M.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-6733","authenticated-orcid":false,"given":"Mai S","family":"Korkor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Elmougy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sobh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa H","family":"Elnagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00467-020-04733-x","volume":"36","author":"A Godron-Dubrasquet","year":"2021","unstructured":"Godron-Dubrasquet A, Woillard J-B, Decramer S, Fila M, Guigonis V, Tellier S, et al. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol. 2021;36:341\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1074_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","volume":"65","author":"CH Feldman","year":"2013","unstructured":"Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarc\u00f3n GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000\u20132004. Arthr Rhuem. 2013;65(3):753\u201363.","journal-title":"Arthr Rhuem"},{"issue":"1","key":"1074_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nep.12136","volume":"19","author":"CC Mok","year":"2014","unstructured":"Mok CC, Yap DYH, Navarra SV, Liu Z, Mh Z, Lu L, et al. Overview of lupus nephritis management guidelines and perspective from a sia. Nephrology. 2014;19(1):11\u201320.","journal-title":"Nephrology"},{"key":"1074_CR4","doi-asserted-by":"crossref","unstructured":"Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10).","DOI":"10.7759\/cureus.30330"},{"issue":"1","key":"1074_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1191\/0961203305lu2053oa","volume":"14","author":"M Aringer","year":"2005","unstructured":"Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus. 2005;14(1):13\u20138.","journal-title":"Lupus"},{"issue":"3","key":"1074_CR6","first-page":"165","volume":"40","author":"MH Park","year":"2006","unstructured":"Park MH. International Society of Nephrology\/Renal Pathology Society 2003 Classification of Lupus Nephritis. J Pathol Translational Med. 2006;40(3):165\u201375.","journal-title":"J Pathol Translational Med"},{"issue":"1","key":"1074_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.ajkd.2012.08.041","volume":"61","author":"LK Henderson","year":"2013","unstructured":"Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GFM, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74\u201387.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1074_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","volume":"70","author":"SC Palmer","year":"2017","unstructured":"Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017;70(3):324\u201336.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1074_CR9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/ndt\/gfm066","volume":"22","author":"B Zhu","year":"2007","unstructured":"Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dialysis Transplantation. 2007;22(7):1933\u201342.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"10","key":"1074_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/tri.12382","volume":"27","author":"P Li","year":"2014","unstructured":"Li P, Shuker N, Hesselink DA, van Schaik RHN, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with caucasian or African American patients? Transpl Int. 2014;27(10):994\u20131004.","journal-title":"Transpl Int"},{"issue":"5","key":"1074_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/tri.12554","volume":"28","author":"T van Gelder","year":"2015","unstructured":"van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28(5):508\u201315.","journal-title":"Transpl Int"},{"issue":"7","key":"1074_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203313486949","volume":"22","author":"W Kittanamongkolchai","year":"2013","unstructured":"Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, et al. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus. 2013;22(7):727\u201332.","journal-title":"Lupus"},{"issue":"11","key":"1074_CR13","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1093\/ndt\/gfn360","volume":"23","author":"I Neumann","year":"2008","unstructured":"Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dialysis Transplantation. 2008;23(11):3514\u201320.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"1","key":"1074_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ndt\/gfy026","volume":"34","author":"N Pourafshar","year":"2019","unstructured":"Pourafshar N, Karimi A, Wen X, Sobel E, Pourafshar S, Agrawal N, et al. The utility of trough mycophenolic acid levels for the management of lupus nephritis. Nephrol Dialysis Transplantation. 2019;34(1):83\u20139.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"5","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/ndt\/gfy284","volume":"35","author":"DYH Yap","year":"2020","unstructured":"Yap DYH, Tam CH, Yung S, Wong S, Tang CSO, Mok TMY, et al. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrol Dialysis Transplantation. 2020;35(5):810\u20138.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"1\u20134","key":"1074_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.trim.2013.05.005","volume":"29","author":"D Vu","year":"2013","unstructured":"Vu D, Tellez-Corrales E, Yang J, Qazi Y, Shah T, Naraghi R, et al. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1\u03b1 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transpl Immunol. 2013;29(1\u20134):155\u201361.","journal-title":"Transpl Immunol"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clinms.2017.07.001","volume":"3","author":"SD Merrigan","year":"2017","unstructured":"Merrigan SD, Kish-Trier E, Seegmiller JC, Johnson-Davis KL. LC\u2013MS\/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clin Mass Spectrom. 2017;3:41\u20138.","journal-title":"Clin Mass Spectrom"},{"issue":"2","key":"1074_CR18","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u0146ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rhuematol. 2002;29(2):288\u201391.","journal-title":"J Rhuematol"},{"issue":"5","key":"1074_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/rheumatology\/keq376","volume":"50","author":"C-S Yee","year":"2011","unstructured":"Yee C-S, Farewell VT, Isenberg DA, Griffiths B, Teh L-S, Bruce IN, et al. The use of systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology. 2011;50(5):982\u20138.","journal-title":"Rheumatology"},{"issue":"8","key":"1074_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/00365513.2016.1230775","volume":"76","author":"O Rissling","year":"2016","unstructured":"Rissling O, Bauer S, Shipkova M, Glander P, Mai M, Hambach P, et al. Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. Scand J Clin Lab Investig. 2016;76(8):612\u20139.","journal-title":"Scand J Clin Lab Investig"},{"issue":"4","key":"1074_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","volume":"23","author":"LM Shaw","year":"2001","unstructured":"Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23(4):305\u201315.","journal-title":"Ther Drug Monit"},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2093","volume":"8","author":"RA Moore","year":"2006","unstructured":"Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Therapy. 2006;8:1\u201310.","journal-title":"Arthritis Res Therapy"},{"issue":"3","key":"1074_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.kint.2019.01.002","volume":"95","author":"AM Schijvens","year":"2019","unstructured":"Schijvens AM, Ehren R, Weber LT, Schreuder MF. The quest for optimal control of relapses in children with nephrotic syndrome. Kidney Int. 2019;95(3):717.","journal-title":"Kidney Int"},{"issue":"2","key":"1074_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/injr.injr_130_21","volume":"17","author":"N Kirubakaran","year":"2022","unstructured":"Kirubakaran N, Punnen A, Prabha R, Agarwal I, Kumar S. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of pediatric lupus nephritis: a cross-sectional study. Indian J Rheumatol. 2022;17(2):124\u20138.","journal-title":"Indian J Rheumatol"},{"issue":"2","key":"1074_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425255.2021.1843633","volume":"17","author":"R Ehren","year":"2021","unstructured":"Ehren R, Schijvens AM, Hackl A, Schreuder MF, Weber LT. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opin Drug Metab Toxicol. 2021;17(2):201\u201313.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1074_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DRJ Kuypers","year":"2010","unstructured":"Kuypers DRJ, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5(2):341\u201358.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1074_CR27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/tid.12275","volume":"16","author":"L Fu","year":"2014","unstructured":"Fu L, Huang Z, Song T, He S, Zeng D, Rao Z, et al. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single\u2010center cohort study in Chinese living\u2010related kidney transplantation. Transpl Infect Disease. 2014;16(5):760\u20136.","journal-title":"Transpl Infect Disease"},{"issue":"12","key":"1074_CR28","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1097\/TP.0b013e3182921995","volume":"95","author":"C Borni-Duval","year":"2013","unstructured":"Borni-Duval C, Caillard S, Olagne J, Perrin P, Braun-Parvez L, Heibel F, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013;95(12):1498\u2013505.","journal-title":"Transplantation"},{"key":"1074_CR29","doi-asserted-by":"crossref","unstructured":"Sagcal-Gironella ACP, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, et al. editors. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus2011: Elsevier.","DOI":"10.1016\/j.semarthrit.2010.05.007"},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00228-019-02701-5","volume":"75","author":"J Sobiak","year":"2019","unstructured":"Sobiak J, Resztak M, Pawi\u0144ski T, \u017bero P, Ostalska-Nowicka D, Zachwieja J, et al. Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study. Eur J Clin Pharmacol. 2019;75:1249\u201359.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1074_CR31","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y Le Meur","year":"2007","unstructured":"Le Meur Y, B\u00fcchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7(11):2496\u2013503.","journal-title":"Am J Transplant"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01074-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T22:36:30Z","timestamp":1741818990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01074-7","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) of Mansoura University (Approval number: R.21.11.1503). All included patients and their legal guardians were informed about the study. This work has been conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}